An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

drug protocol number
M14-423
drug sponsor
AbbVie
drug study
ABT-450/r/ABT-267+ABT-333 (-/+) Ribavirin (RBV)
drug trial site
KKUH
drug status
Ongoing
drug phase